Sarcoma / 2017 / Article / Tab 1

Clinical Study

SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors

Table 1

Patient characteristics at enrollment and response evaluation.

Stratum NF1 MPNST Sporadic MPNST

Eligible patients enrolled3414

Male/female22/129/5

Median age: years (range)33 (8–66)40 (13–72)

Race: (%)
 White, non-Hispanic14 (41%)11 (79%)
 Black13 (38%)2 (14%)
 Hispanic4 (12%)0 (0%)
 Other/unknown3 (9%)1 (7%)

ECOG score: 0/1/24/24/66/5/3

Disease: localized/metastatic18/165/9

Location
 Head20
 Neck31
 Chest104
 Abdomen/pelvis95
 Spine51
 Upper extremity31
 Lower extremity22

Response evaluation after cycle 4289

Complete response (CR)
Partial response (PR)54
Stable disease (SD)204
Progressive disease (PD)31

Objective response rate: %17.944.4

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.